Call Us: 1.800.873.5297

By

FDA Recall & Safety Alerts

FDA Recall & Safety Alerts

The Food and Drug Administration (FDA) is the government agency that monitors and regulates over-the-counter medications, prescription drugs, dietary supplements and other medical products in the United States. In an effort to provide the public with timely information on the products it monitors, the FDA releases safety alerts with information that may impact treatment and diagnostic choices for patients and healthcare professionals.

The pharmaceutical injury attorneys at Schlichter, Bogard & Denton want you to have the latest information released by the FDA. Please view the most recent FDA safety alerts and click on the link to learn more about the alert for these products.

Camolyn eye drops & Fisiolin nasal drops- Non-sterility voluntary recall

April 07, 2010 – US Oftalmi and the FDA posted notice of the nationwide recall of all over-the-counter eye drops and nasal drops. This recall was initiated due to conditions at the manufacturing facility that may affect the sterility of the products. Products that are non-sterile have the potential to cause eye infections that could lead to loss of sight. Read more.

Stalevo – FDA Ongoing Safety Review

Mar. 31, 2010- The FDA provided notice that it is evaluating data from a long-term clinical trial called Stalevo Reduction in Dyskinesia Evaluation – Parkinson’s Disease (STRIDE-PD). This trial may suggest patients taking Stalevo may be at an increased risk for the development of prostate cancer. Read more.

Cleviprex – Recall Update

Mar. 17, 2010- The Cleviprex recall announced earlier this year has been expanded to include four additional lots. The Medicines Company announced it is voluntarily expanding the recall of the injectable emulsion, Cleviprex. Read more.

Plavix – Reduced effectiveness in patients who are poor metabolizers of the drug

Mar. 12, 2010 – The FDA announced that a Boxed Warning has been added to the prescribing information for Plavix, an anti-blood clotting medication. Read more.

WinRho SDF – Risk of Intravascular Hemolysis

Mar. 10, 2010 – Cangene, Baxter and the FDA announced that notification has been sent to healthcare professional alerting them of cases of intravascular hemolysis (IVH) and its complications, including fatalities, have been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF.Read more.

Invirase – Ongoing safety review of clinical trial data

Feb.23, 2010 – FDA notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart from the use of Invirase (saquinavir) in combination with Norvir (ritonavir), antiviral medications given together to treat HIV infection. Read more.

Avandia – Ongoing Review of Cardiovascular Safety

Feb. 22, 2010 – The FDA sent notification to healthcare professional and patients that it will be reviewing the primary data from the clinical study, RECORD, on possible cardiovascular risks with Avandia, a diabetes drug. A number of observational studies of the cardiovascular safety of Avandia have been published. The FDA has been reviewing these on an ongoing basis, in addition to the clinical trial. Read more.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.